CHEK - Check-Cap Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.0700
+0.0500 (+2.48%)
At close: 4:00PM EDT

2.0700 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous Close2.0200
Open2.0900
Bid1.9800 x 800
Ask2.1000 x 800
Day's Range1.9900 - 2.0900
52 Week Range1.6200 - 4.5000
Volume18,499
Avg. Volume112,946
Market Cap17.054M
Beta (3Y Monthly)1.68
PE Ratio (TTM)N/A
EPS (TTM)-1.8890
Earnings DateMar 7, 2019 - Mar 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Trade prices are not sourced from all markets
  • Check-Cap and GE Healthcare Announce Completion of Manufacturing Line Transfer Implementation and Qualification for the C-Scan® System Operated by GE Healthcare
    PR Newswire3 days ago

    Check-Cap and GE Healthcare Announce Completion of Manufacturing Line Transfer Implementation and Qualification for the C-Scan® System Operated by GE Healthcare

    GE Healthcare facility in Chicago to support clinical investigation needs of the C-Scan® System in the U.S. ISFIYA, Israel , Aug. 19, 2019 /PRNewswire/ --  Check-Cap Ltd. (the "Company" or "Check-Cap") ...

  • Check-Cap Reports Second Quarter 2019 Financial Results and Corporate Highlights
    PR Newswire15 days ago

    Check-Cap Reports Second Quarter 2019 Financial Results and Corporate Highlights

    Reported positive final results from post-CE approval study of the C-Scan® System ISFIYA, Israel , Aug. 7, 2019 /PRNewswire/ --  Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: ...

  • Check-Cap Announces Positive Final Results from Its Post-CE Approval Study of the C-Scan® System
    PR Newswirelast month

    Check-Cap Announces Positive Final Results from Its Post-CE Approval Study of the C-Scan® System

    ISFIYA, Israel, July 9, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (NASDAQ:CHEKW), (NASDAQ:CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free capsule based screening method for the prevention of colorectal cancer through the detection of precancerous polyps, today announced positive final results from its recently completed post-CE approval study evaluating the clinical performance and safety of the C-Scan system. The study included 90 evaluable patients who either had known polyps or were considered to be of average risk.

  • Check-Cap Appoints Joshua (Shuki) Belkar as Vice President of Operations
    PR Newswire3 months ago

    Check-Cap Appoints Joshua (Shuki) Belkar as Vice President of Operations

    Mr. Belkar Brings More Than 20 Years of Global Medical Device Experience, Including at Medtronic and Mazor Robotics ISFIYA, Israel , June 3, 2019 /PRNewswire/ --  Check-Cap Ltd. (the "Company" ...

  • Check-Cap to Present Data at Digestive Disease Week® Demonstrating Substantial Improvement in Precancerous Polyp Detection
    PR Newswire3 months ago

    Check-Cap to Present Data at Digestive Disease Week® Demonstrating Substantial Improvement in Precancerous Polyp Detection

    ISFIYA, Israel , May 16, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company ...

  • Check-Cap Reports First Quarter 2019 Financial Results
    PR Newswire3 months ago

    Check-Cap Reports First Quarter 2019 Financial Results

    Initiates U.S. pilot study of C-Scan® at NYU School of Medicine and Mayo Clinic ISFIYA, Israel , May 13, 2019 /PRNewswire/ --  Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: ...

  • Check-Cap Announces Second Trial Site Joins Ongoing U.S. Pilot Study of C-Scan®
    PR Newswire3 months ago

    Check-Cap Announces Second Trial Site Joins Ongoing U.S. Pilot Study of C-Scan®

    Mayo Clinic joins New York University in pilot study of C-Scan® in the U.S. ISFIYA, Israel, May 13,  2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (NASDAQ:CHEKW), (NASDAQ:CHEKZ), a clinical-stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free ingestible capsule for the prevention of colorectal cancer through the detection of precancerous polyps, today announced that Mayo Clinic is the second trial site participating in the Company's ongoing pilot study of the C-Scan® system in the U.S.

  • Check-Cap Initiates U.S. Pilot Study of C-Scan® for Colorectal Cancer Screening
    PR Newswire4 months ago

    Check-Cap Initiates U.S. Pilot Study of C-Scan® for Colorectal Cancer Screening

    ISFIYA, Israel, April 8, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (NASDAQ:CHEKW), (NASDAQ:CHEKZ), a clinical-stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free ingestible capsule for the prevention of colorectal cancer through the detection of precancerous polyps, today announced the initiation of its U.S. pilot study of the C-Scan® system, following Institutional Review Board (IRB) approval and full Investigational Device Exemption (IDE) application approval by the U.S. Food and Drug Administration (FDA). The first patients have ingested the C-Scan® capsule at the New York University School of Medicine. "The pilot study initiation is a critical milestone on our path for developing and potentially commercializing the C-Scan® system in the U.S.," said Alex Ovadia, chief executive officer of Check-Cap.

  • Check-Cap Reports Fourth Quarter and Full-Year 2018 Financial Results
    PR Newswire5 months ago

    Check-Cap Reports Fourth Quarter and Full-Year 2018 Financial Results

    ISFIYA, Israel , March 28, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company ...

  • Check-Cap Announces Appointment of Mira Rosenzweig as Chief Financial Officer
    PR Newswire5 months ago

    Check-Cap Announces Appointment of Mira Rosenzweig as Chief Financial Officer

    ISFIYA, Israel , March 18, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (Nasdaq: CHEK) (Nasdaq: CHEKW), (Nasdaq: CHEKZ), a clinical stage medical diagnostics company ...

  • Check-Cap Announces Institutional Review Board Approval to Initiate U.S. Pilot Study of C-Scan®
    PR Newswire6 months ago

    Check-Cap Announces Institutional Review Board Approval to Initiate U.S. Pilot Study of C-Scan®

    ISFIYA, Israel, Feb. 12, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (CHEKW), (CHEKZ), a clinical-stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free capsule based screening method for the prevention of colorectal cancer through the detection of precancerous polyps, today announced it has received Institutional Review Board (IRB) approval from New York University School of Medicine to initiate a U.S. pilot study of the C-Scan® system. "We are excited to receive IRB approval as this important milestone enables Check-Cap to bring the C-Scan® system into the clinic in the U.S.," said Alex Ovadia, chief executive officer of Check-Cap.

  • Check-Cap Ltd. Announces Closing of $7.5 Million Registered Direct Offering
    PR Newswire6 months ago

    Check-Cap Ltd. Announces Closing of $7.5 Million Registered Direct Offering

    ISFIYA, Israel, Feb. 7, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (NASDAQ:CHEKW), (CHEKZ), a clinical-stage medical diagnostics company offering C-Scan®, the first and only preparation free capsule-based screening method for the prevention of colorectal cancer through the detection of precancerous polyps, today announced the closing of its previously announced registered direct offering with certain institutional investors for the purchase of 2,906,376 units, at a purchase price of $2.58 per unit. Each unit consisted of (i) one ordinary share (or ordinary share equivalent), and (ii) a warrant to purchase one half ordinary share.

  • Check-Cap Ltd. Announces $7.5 Million Registered Direct Offering
    PR Newswire7 months ago

    Check-Cap Ltd. Announces $7.5 Million Registered Direct Offering

    ISFIYA, Israel, Feb. 4, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (NASDAQ:CHEKW), (CHEKZ), a clinical-stage medical diagnostics company offering C-Scan®, the first and only preparation free capsule-based screening method for the prevention of colorectal cancer through the detection of precancerous polyps, today announced that it has entered into definitive agreements with institutional investors for the purchase of 2,906,376 units, at a purchase price of $2.58 per unit, in a registered direct offering. Each unit consists of (i) one ordinary share (or ordinary share equivalent), and (ii) a warrant to purchase one half ordinary share.

  • PR Newswire8 months ago

    Check-Cap Announces FDA Conditional Approval of IDE to Initiate U.S. Pilot Study of C-Scan®

    Study to begin upon review and approval of Institutional Review Board (IRB) ISFIYA, Israel , Dec. 13, 2018 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) ...

  • GlobeNewswire9 months ago

    Analysis: Positioning to Benefit within Autoliv, Science Applications International, Trecora Resources, Ardmore Shipping, Check-Cap, and Sharps Compliance — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 13, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Check-Cap Reports Third Quarter 2018 Financial Results
    PR Newswire10 months ago

    Check-Cap Reports Third Quarter 2018 Financial Results

    Announced Interim Results from Post-CE Approval Study of C-Scan® Announces Update on Scheduled Initiation of U.S. Pilot Study ISFIYA, Israel , Nov. 5, 2018 /PRNewswire/ --  Check-Cap Ltd. (the "Company" ...

  • PR Newswire10 months ago

    Check-Cap Announces IDE Submission to FDA for Its C-Scan® System

    If Approved, U.S. Pilot Study Anticipated to Commence in 4Q 2018 ISFIYA, Israel , Oct. 9, 2018 /PRNewswire/ --  Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: ...

  • Check-Cap Receives Approval From the Israeli Ministry of Health to Initiate Commercial Sales in Israel of its C-Scan® System
    PR Newswirelast year

    Check-Cap Receives Approval From the Israeli Ministry of Health to Initiate Commercial Sales in Israel of its C-Scan® System

    ISFIYA, Israel, Sept. 5, 2018 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (CHEKW) (CHEKZ), a clinical-stage medical diagnostics company engaged in the development of C-Scan®, an ingestible capsule for preparation-free, colorectal cancer (CRC) screening, today announced it has received approval from the Israeli Ministry of Health, the Medical Device Division (known as "AMAR"), to initiate commercial sales in Israel of the C-Scan system that received CE Mark approval in January 2018. Alex Ovadia, Chief Executive Officer of Check-Cap, commented, "We are excited to receive approval from the Israeli Ministry of Health to initiate commercial sales in Israel of our C-Scan system.

  • PR Newswirelast year

    Check-Cap Announces Promising Interim Results from its Ongoing Post-CE Approval Study of C-Scan® System Version 3

    ISFIYA, Israel, Sept. 4, 2018 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (CHEKW) (CHEKZ), a clinical-stage medical diagnostics company engaged in the development of C-Scan®, an ingestible capsule-based device for preparation-free, colorectal cancer (CRC) screening, today announced the interim results for its post-CE approval study of the C-Scan system Version 3. Data from the multi-center clinical investigation showed promising results for detecting patients with polyps in an un-prepped colon. The objective of the study is to assess safety and clinical performance of the C-Scan system Version 3 in detecting patients with polyps.

  • Check-Cap Announces Participation at the 20th Annual Rodman & Renshaw Global Investment Conference
    PR Newswirelast year

    Check-Cap Announces Participation at the 20th Annual Rodman & Renshaw Global Investment Conference

    ISFIYA, Israel, Aug. 29, 2018 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (CHEKW) (CHEKZ), a clinical stage medical diagnostics company engaged in the development of C-Scan®, an ingestible capsule-based device for preparation-free colorectal cancer screening, today announced it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.  The conference is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City. If you are an institutional investor, and would like to attend the Company's presentation, please click on the following link (www.rodmanevents.com ) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.